Stemline Therapeutics, Inc. (STML) Earns “Buy” Rating from Cowen and Company

Cowen and Company reiterated their buy rating on shares of Stemline Therapeutics, Inc. (NASDAQ:STML) in a report published on Wednesday morning.

Several other equities research analysts have also recently issued reports on STML. Zacks Investment Research raised shares of Stemline Therapeutics from a sell rating to a hold rating in a research report on Saturday, May 20th. HC Wainwright set a $34.00 target price on shares of Stemline Therapeutics and gave the stock a buy rating in a research report on Monday, February 27th. ValuEngine cut shares of Stemline Therapeutics from a hold rating to a sell rating in a research report on Wednesday, May 31st. Wedbush reissued an outperform rating and issued a $11.00 target price on shares of Stemline Therapeutics in a research report on Friday, March 17th. Finally, Jefferies Group LLC reissued a buy rating and issued a $16.00 target price on shares of Stemline Therapeutics in a research report on Thursday, May 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $29.17.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at 8.30 on Wednesday. The stock has a 50 day moving average of $8.08 and a 200-day moving average of $9.28. The stock’s market capitalization is $194.02 million. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative return on equity of 60.51% and a negative net margin of 3,864.20%. The company had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. Equities research analysts predict that Stemline Therapeutics will post ($2.27) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Stemline Therapeutics, Inc. (STML) Earns “Buy” Rating from Cowen and Company” was reported by sleekmoney and is the property of of sleekmoney. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://sleekmoney.com/stemline-therapeutics-inc-stml-earns-buy-rating-from-cowen-and-company/1920378.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares during the period. AXA acquired a new position in shares of Stemline Therapeutics during the first quarter worth $3,712,000. Renaissance Technologies LLC boosted its position in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares during the period. State Street Corp boosted its position in shares of Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock worth $2,694,000 after buying an additional 21,296 shares during the period. Finally, Bailard Inc. boosted its position in shares of Stemline Therapeutics by 12.1% in the first quarter. Bailard Inc. now owns 138,785 shares of the biopharmaceutical company’s stock worth $1,187,000 after buying an additional 15,000 shares during the period. 54.18% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/stemline-therapeutics-inc-stml-earns-buy-rating-from-cowen-and-company/1920378.html

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *